nifurtimox and Postoperative-Complications

nifurtimox has been researched along with Postoperative-Complications* in 1 studies

Other Studies

1 other study(ies) available for nifurtimox and Postoperative-Complications

Article	Year
[Prophylaxis against Chagas disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation]. Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2012, Volume: 29 Suppl 1 Chagas disease is a zoonosis caused by T. cruzi. The estimated prevalence in endemic areas is 0.6-0.9 / 100,000. In immunocompromised behaves as an opportunistic pathogen highly aggressive and can evolve with meningoencephalitis, myocarditis or systemic disease. We recommend obtaining serology for all donor and recipient of SOT and HSCT. An infected donor should be discarded as such. In the case of D (-) R (+) exists controversy between prophylaxis and pre emptive therapy. The chosen drug for prophylaxis is nifurtimox for 3 months, effective but with relevant adverse effects. Monitoring should be done with RPC and MicroStrout weekly until six months post-transplant, then on a monthly basis for the duration of immunosuppression and continued for life clinical monitoring (C3). Topics: Adult; Chagas Disease; Child; Drug Administration Schedule; Follow-Up Studies; Humans; Nifurtimox; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Stem Cell Transplantation; Trypanocidal Agents	2012

Article

Year

[Prophylaxis against Chagas disease in pediatric and adult patients undergoing solid organ and hematopoietic stem cells transplantation].

Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia, 2012, Volume: 29 Suppl 1

Chagas disease is a zoonosis caused by T. cruzi. The estimated prevalence in endemic areas is 0.6-0.9 / 100,000. In immunocompromised behaves as an opportunistic pathogen highly aggressive and can evolve with meningoencephalitis, myocarditis or systemic disease. We recommend obtaining serology for all donor and recipient of SOT and HSCT. An infected donor should be discarded as such. In the case of D (-) R (+) exists controversy between prophylaxis and pre emptive therapy. The chosen drug for prophylaxis is nifurtimox for 3 months, effective but with relevant adverse effects. Monitoring should be done with RPC and MicroStrout weekly until six months post-transplant, then on a monthly basis for the duration of immunosuppression and continued for life clinical monitoring (C3).

Topics: Adult; Chagas Disease; Child; Drug Administration Schedule; Follow-Up Studies; Humans; Nifurtimox; Organ Transplantation; Postoperative Complications; Practice Guidelines as Topic; Stem Cell Transplantation; Trypanocidal Agents

2012